Pioneer Research is a pre-clinical stage discovery and development enterprise established in 2022. We are located centrally on Montebello in Oslo, conveniently near our close collaboration partners in the leading academic environment at the Medical Faculty and Mathematics and Natural Science Faculty at the University of Oslo, and the clinical environment at Oslo University Hospital. We are currently establishing our proprietary miPCancer Discovery and Development Platform for commercialization and advancing the pre-clinical development of our lead inhibitor PR-2304 toward clinical trials.

The Team

Emily Martinsen, M.Sc
COO, Co-founder
More…

After graduating from the University Utah, US, Emily was recruited to work in the US’s competitive pharmaceutical Industry, igniting her interest in developing an improved knowledge-based treatment for tomorrow’s patients. She returned to Norway for her master’s degree in transcription factor regulation in cancer at the Medical Faculty at the University of Oslo (3,4). She co-founded Pioneer Research to contribute innovative solutions and strategies to develop the PR-2304 lead program and commercialize the miPCancer Platform.

 

Tasmia Jinnurine, M.Sc
Laboratory Engineer
More…

Tasmia has international experience in pharmaceutical production, quality control, and documentation. She has in debt knowledge of versatile molecular and cellular assays and contributes to establishing the commercial setup and daily running of our platform service.

Stian Rogne
Co-founder
More…

Stian is a co-founder of Pioneer Research. Stian has extensive experience with business development and entrepreneurship. He has a strong drive for innovation and profitability and broad experience from various boards and leading large inter-company collaborative projects. He has been involved in developing several companies to success over the past 20 years.

 

References

  1. Rogne, Marie; Svärd, Oksana; Madsen-Østerbye, Julia-Kristina Jensen; Hashim, Adnan; Tjønnfjord, Geir Erland & Staerk, Judith (2018). Cytokinesis arrest and multiple centrosomes in B cell chronic lymphocytic leukaemia. Journal of Cellular and Molecular Medicine. ISSN 1582-1838. 22(5), p. 2846–2855. doi: 10.1111/jcmm.13579.
  2. Fuglerud, Bettina Maria; Ledsaak, Marit; Rogne, Marie; Eskeland, Ragnhild & Gabrielsen, Odd Stokke (2018). The pioneer factor activity of c-Myb involves recruitment of p300 and induction of histone acetylation followed by acetylation-induced chromatin dissociation. Epigenetics & Chromatin. ISSN 1756-8935. 11(1). doi: 10.1186/s13072-018-0208-y.
  3. Martinsen, E. (2021). Identification of the Active Transcription Factor Network in Osteosarcoma [Master’s thesis, University of Oslo]. DUO. https://www.duo.uio.no/handle/10852/89902.
  4. Lemma, R.B., Fleischer, T., Martinsen, E. et al. Pioneer transcription factors are associated with the modulation of DNA methylation patterns across cancers. Epigenetics & Chromatin 15, 13 (2022). https://doi.org/10.1186/s13072-022-00444-9.